HHS freezes Trump administration rule on insulin, epinephrine drug discounts

Listen
Text
  • Small
  • Medium
  • Large

HHS has frozen a rule implemented by former President Donald Trump that requires federally qualified health centers to pass discounts on insulin and epinephrine directly to patients. 

The rule was supposed to take effect Jan. 22 but is now delayed until March 22, HHS said Jan. 21. The department said the purpose of the delay is to give department officials the opportunity to further review the rule. 

The rule requires all health centers receiving section 330(e) grant funds and participating in the 340B drug-pricing program to make insulin and epinephrine available to low-income patients at or below the cost the health center purchased them through the 340B drug-pricing program.

It was part of an executive order signed by former President Trump July 24 and applies to people with annual incomes at or below 350 percent of the federal poverty level who have a high cost-sharing requirement, high unmet deductible or no health insurance. 

More articles on pharmacy:
Merck abandons its 2 COVID-19 vaccine candidates
FDA approves first monthly injectable to treat HIV
Amazon, Seattle health system create vaccination pop-up site

Copyright © 2021 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars